A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Anlotinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 27 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 according to ClinicalTrials.gov record.